RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Highlights from the Science family of journals.
RESUMEN
Mucosal delivery of IL-27 has been shown to have a therapeutic benefit in murine models of inflammatory bowel disease (IBD). The IL-27 effect was associated with phosphorylated STAT1 (pSTAT1), a product of IL27 receptor signaling, in bowel tissue. To determine whether IL-27 acted directly on colonic epithelium, murine colonoids and primary intact colonic crypts were shown to be unresponsive to IL-27 in vitro and to lack detectable IL-27 receptors. On the other hand, macrophages, which are present in inflamed colon tissue, were responsive to IL-27 in vitro. IL-27 induced pSTAT1 in macrophages, the transcriptome indicated an IFN-like signature, and supernatants induced pSTAT1 in colonoids. IL-27 induced anti-viral activity in macrophages and MHC Class II induction. We conclude that the effects of mucosal delivery of IL-27 in murine IBD are in part based on the known effects of IL27 inducing immunosuppression of T cells mediated by IL-10. We also conclude that IL-27 has potent effects on macrophages in inflamed colon tissue, generating mediators that in turn act on colonic epithelium.
Asunto(s)
Enfermedades Inflamatorias del Intestino , Interleucina-27 , Ratones , Animales , Interleucina-27/uso terapéutico , Colon , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Macrófagos , EpitelioRESUMEN
Highlights from the Science family of journals.